Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
risvutatug rezetecan
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Risvutatug rezetecan** is a novel B7-H3-targeted antibody-drug conjugate (ADC) composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase I inhibitor (TOP1i) payload. It selectively binds to B7-H3, a cell surface protein overexpressed in various solid tumors, enabling targeted delivery of the cytotoxic payload to induce DNA damage and tumor cell death. Developed originally by Hansoh Pharmaceutical with exclusive worldwide rights (ex-China, Hong Kong, Macau, Taiwan) licensed to GSK, it has shown promising antitumor activity in heavily pretreated patients across multiple solid tumors, including high response rates in small cell lung cancer (SCLC) and osteosarcoma, with a manageable safety profile primarily featuring hematologic toxicities.[1][3][7]
- Other names
- anti-B7-H3 antibody-drug conjugate HS-20093anti-B-7-H3 antibody-drug conjugate HS-20093anti-B 7-H3 antibody-drug conjugate HS-20093
02
Targets
B7-H3TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on risvutatug rezetecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on risvutatug rezetecan.